Syeda Seirut Javed
Sun, December 7, 2025 astatine 11:32 PM CST 3 min read
Merck & Co., Inc. (NYSE:MRK) is 1 of the stocks Jim Cramer discussed, on with the tech battleground. Cramer highlighted the company’s strategical readying for erstwhile Keytruda loses patent protection. He commented:
“The radical who tally this institution are not idiots. They’ve agelong known that Keytruda would suffer patent protection, so, for years, they’ve been making acquisitions to physique up their pipeline… Verona is focused connected respiratory diseases, and they already person 1 cause connected the market, the archetypal caller attraction attraction for chronic obstructive pulmonary illness successful much than 20 years. It volition beryllium different blockbuster, I predict…So, Merck’s been making ample mentation for a satellite without Keytruda exclusivity, and the analysts are starting to notice. Last Monday, Wells Fargo upgraded the stock… enactment entitled, ‘we tin spot a aboriginal beyond Keytruda.’
A idiosyncratic with banal marketplace information connected a laptop. Photo by Anna Nekrashevich connected Pexels
Merck & Co., Inc. (NYSE:MRK) is simply a healthcare institution that provides a wide scope of quality and veterinary pharmaceuticals, vaccines, and wellness solutions.
While we admit the imaginable of MRK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

1 month ago
10



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·